Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$231.6M
+33.9% from 2023
Prescriptions
41K
$5,692.79 per claim
Patients
8,488
5,020 prescribers
Total spending, 2024
$231.7M
$27,288.30 per patient
Medicare prescription drug plans paid $231.6M for Fasenra Pen in 2024, for 40,690 prescriptions and refills to 8,488 patients (up 33.9% from 2023). The average cost per claim was $5,692.79.
New York had the highest Medicare cost for Fasenra Pen in 2024: $17.9M for 3,187 claims, followed by California ($16.9M).
Ashley R Haskin, physician assistant in Raleigh, NC, had the highest Medicare cost for Fasenra Pen in 2024: 93 claims costing $547K.
Fasenra Pen is made by AstraZeneca PLC (AZN), listed in the Medicare spending data as Astrazeneca.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Ashley R Haskin Raleigh, NC | Physician Assistant | 93 | 16 | $547K |
| David S Wilson Seymour, IN | Pulmonary Disease | 83 | 15 | $496K |
| Njira L Lugogo |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 3,145 | 21,124 | 4,749 | $119.1M |
| 2023 | 4,029 | 29,525 | 6,317 | $172.9M |
| 2024 | 5,020 | 40,690 | 8,488 | $231.6M |
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Pulmonary Disease |
| 86 |
| 21 |
| $464K |
| Rebecca B Ezell Slidell, LA | Nurse Practitioner | 87 | 17 | $461K |
| Philip Slocum Joplin, MO | Pulmonary Disease | 80 | 15 | $434K |
| Prashanth Thalanayar Muthukrishnan Douglasville, GA | Pulmonary Disease | 77 | 14 | $431K |
| Michael A Imevbore New Haven, CT | Pulmonary Disease | 70 | 17 | $410K |
| Allison Friedenberg San Francisco, CA | Internal Medicine | 75 | 14 | $403K |
| Arturo A Meade Fort Smith, AR | Pulmonary Disease | 66 | 12 | $392K |
| Lisa I Mansur Lincoln, NE | Pulmonary Disease | 64 | Under 11 | $380K |
| Shyamsunder Subramanian Tracy, CA | Pulmonary Disease | 69 | 18 | $379K |
| Michael J Coffey Ann Arbor, MI | Pulmonary Disease | 65 | 11 | $359K |
| Frances E Lee Atlanta, GA | Pulmonary Disease | 65 | 13 | $359K |
| Wendy B Gilraine Martinsville, VA | Nurse Practitioner | 61 | 11 | $354K |
| Jessica L Thompson Tyler, TX | Nurse Practitioner | 64 | 17 | $348K |
| Rani R Vatti Roseville, CA | Internal Medicine | 63 | 14 | $339K |
| Samuel Louie Sacramento, CA | Pulmonary Disease | 55 | Under 11 | $337K |
| Thuy Lien D Lai Riverside, CA | Allergy/ Immunology | 62 | Under 11 | $333K |
| Akram M Shibani Jacksonville, FL | Pulmonary Disease | 58 | 12 | $328K |
| Herbon E Fleming Burlington, NC | Pulmonary Disease | 53 | Under 11 | $328K |
| Douglas M Beach Boston, MA | Pulmonary Disease | 58 | 14 | $326K |
| Emily J Littman Philadelphia, PA | Physician Assistant | 58 | 17 | $320K |
| Kara F Strippoli Hamden, CT | Physician Assistant | 56 | 12 | $314K |
| Jessica F Most Philadelphia, PA | Pulmonary Disease | 55 | 15 | $307K |
| Erin Macneill Norwood, MA | Nurse Practitioner | 54 | Under 11 | $305K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Astrazeneca AZN | 40,692 | $231.7M |